Download PDF
Thromb Haemost 2016; 115(05): 1073-1075
DOI: 10.1160/TH15-10-0818
Letters to the Editor
Schattauer GmbH

Recurrent VTE in a heterozygote of the fibrinogen Aα IVS4+1G>T and Aα p.Arg168Ter mutation

Christina Berens   *
,
Heiko Rühl   *
,
Vytautas Ivaškevicius
1   Institute of Experimental Haematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany
,
Johannes Oldenburg
1   Institute of Experimental Haematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany
,
Hans-Jörg Hertfelder
1   Institute of Experimental Haematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany
,
Bernd Pötzsch
1   Institute of Experimental Haematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany
› Author Affiliations
Further Information

Publication History

Received: 27 October 2015

Accepted after major revision: 07 January 2015

Publication Date:
06 December 2017 (online)

    Permissions and Reprints

 

* Both authors contributed equally and are listed in alphabetical order.


 

  • References

  • 1 Peyvandi F. Epidemiology and treatment of congenital fibrinogen deficiency. Thromb Res 2012; 130 (Suppl. 02) S7-S11.
    PubMedGoogle Scholar
  • 2 de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost 2013; 39: 585-595.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Teresa SM, Marta M, Emiliano DB. et al. Thrombosis of abdominal aorta in congenital abfibrinogenemia: case report and review of literature. Haemophilia 2015; 21: 88-94.
    CrossrefPubMedGoogle Scholar
  • 4 Solomon C, Gröner A, Ye J. et al. Safety of fibrinogen concentrate: analysis of more than 27 years of pharmacovigilance data. Thromb Haemost 2015; 113: 759-771.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Bornikova L, Peyvandi F, Allen G. et al. Fibrinogen replacement therapy for congenital fibrinogen deficiency. J Thromb Haemost 2011; 9: 1687-1704.
    CrossrefPubMedGoogle Scholar
  • 6 Neerman-Arbez M, de Moerloose P, Bridel C. et al. Mutations in the fibrinogenAa gene account for the majority of cases of congenital afibrinogenemia. Blood 2000; 96: 149-152.
    PubMedGoogle Scholar
  • 7 Neerman-Arbez M, de Moerloose P, Honsberger A. et al. Molecular analysis of the fibrinogen gene cluster in 16 patients with congenital fibrinogenemia: novel truncating mutations in the FGA and FGG genes. Hum Genet 2001; 108: 237-240.
    CrossrefPubMedGoogle Scholar
  • 8 Fellowes AP, Brennan SO, Holme R. et al. Homozygous truncation of the fibrinogen A alpha chain within the coiled coil causes congenital afibrinogenemia. Blood 2000; 96: 773-775.
    PubMedGoogle Scholar
  • 9 Asselta R, Duga S, Spena S. et al. Congenital afibrinogenemia: mutations leading to premature termination codons in fibrinogen A alpha-chain gene are not associated with the decay of the mutant mRNAs. Blood 2001; 98: 3685-3692.
    CrossrefPubMedGoogle Scholar
  • 10 Casini A, Blondon M, Lebreton A. et al. Natural history of patients with congenital dysfibrinogenemia. Blood 2015; 125: 553-561.
    CrossrefPubMedGoogle Scholar
  • 11 Ni H, Denis CV, Subbarao S. et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 2000; 106: 385-392.
    CrossrefPubMedGoogle Scholar
  • 12 Dupuy E, Soria C, Molho P. et. al Embolized ischemic lesions of toes in an aETXbrinogenemic patient: possible relevance to in vivo circulating thrombin. Thromb Res 2001; 102: 211-219.
    CrossrefPubMedGoogle Scholar